Cogent Biosciences (NASDAQ:COGT) Insider Jessica Sachs Sells 82,642 Shares

Cogent Biosciences, Inc. (NASDAQ:COGT) insider Jessica Sachs sold 82,642 shares of the stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $38.70, for a total transaction of $3,198,245.40. Following the completion of the sale, the insider owned 133,938 shares of the company’s stock, valued at approximately $5,183,400.60. The trade was a 38.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Cogent Biosciences Trading Down 2.1%

COGT opened at $37.12 on Wednesday. The firm has a market capitalization of $5.29 billion, a price-to-earnings ratio of -22.63 and a beta of 0.49. The company’s 50 day simple moving average is $32.14 and its two-hundred day simple moving average is $19.03. Cogent Biosciences, Inc. has a 1-year low of $3.72 and a 1-year high of $43.73. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.38 and a quick ratio of 6.38.

Cogent Biosciences (NASDAQ:COGT) last posted its quarterly earnings results on Monday, November 3rd. The technology company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.04. Analysts expect that Cogent Biosciences, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

COGT has been the topic of several recent research reports. HC Wainwright boosted their price target on shares of Cogent Biosciences from $21.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Wedbush upgraded shares of Cogent Biosciences from a “neutral” rating to an “outperform” rating and set a $38.00 target price on the stock in a report on Monday, November 10th. Stifel Nicolaus raised shares of Cogent Biosciences from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research note on Monday, November 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cogent Biosciences in a research report on Monday, December 8th. Finally, Robert W. Baird upped their price objective on Cogent Biosciences from $14.00 to $34.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Cogent Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.82.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its position in shares of Cogent Biosciences by 41.4% during the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after buying an additional 1,333 shares during the period. Strs Ohio acquired a new position in Cogent Biosciences during the 1st quarter worth about $36,000. Ameritas Investment Partners Inc. boosted its holdings in Cogent Biosciences by 16.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 10,839 shares of the technology company’s stock valued at $78,000 after acquiring an additional 1,543 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Cogent Biosciences by 22.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,401 shares of the technology company’s stock valued at $78,000 after acquiring an additional 1,003 shares in the last quarter. Finally, CWM LLC increased its stake in Cogent Biosciences by 25.3% during the third quarter. CWM LLC now owns 5,582 shares of the technology company’s stock worth $80,000 after purchasing an additional 1,126 shares during the period.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.